Hu Fang, Mao Xiaowei, Zhang Yujun, Zheng Xiaoxuan, Gu Ping, Wang Huimin, Zhang Xueyan
Department of Pulmonary Medicine, Shanghai Chest Hospital, Shanghai Jiao Tong University, Shanghai, People's Republic of China.
Onco Targets Ther. 2018 Mar 14;11:1373-1384. doi: 10.2147/OTT.S158479. eCollection 2018.
To evaluate the clinical value of circulating tumor cells as a surrogate to detect epidermal growth factor receptor mutation in advanced non-small-cell lung cancer (NSCLC) patients.
We searched the electronic databases, and all articles meeting predetermined selection criteria were included in this study. The pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio were calculated. The evaluation indexes of the diagnostic performance were the summary receiver operating characteristic curve and area under the summary receiver operating characteristic curve.
Eight eligible publications with 255 advanced NSCLC patients were included in this meta-analysis. Taking tumor tissues as reference, the pooled sensitivity, specificity, positive likelihood ratio, negative likelihood ratio, and diagnostic odds ratio of circulating tumor cells for detecting the epidermal growth factor receptor mutation status were found to be 0.82 (95% confidence interval [CI]: 0.50-0.95), 0.95 (95% CI: 0.24-1.00), 16.81 (95% CI: 0.33-848.62), 0.19 (95% CI: 0.06-0.64), and 86.81 (95% CI: 1.22-6,154.15), respectively. The area under the summary receiver operating characteristic curve was 0.92 (95% CI: 0.89-0.94). The subgroup analysis showed that the factors of blood volume, histological type, EGFR-tyrosine kinase inhibitor therapy, and circulating tumor cell and tissue test methods for EGFR accounted for the significant difference of the pooled specificity. No significant difference was found between the pooled sensitivity of the subgroup.
Our meta-analysis confirmed that circulating tumor cells are a good surrogate for detecting epidermal growth factor receptor mutation when tumor tissue is unavailable in advanced NSCLC patients, but more precise techniques are needed to improve their clinical efficiency.
评估循环肿瘤细胞作为晚期非小细胞肺癌(NSCLC)患者表皮生长因子受体突变检测替代指标的临床价值。
检索电子数据库,纳入所有符合预定选择标准的文章。计算合并敏感度、特异度、阳性似然比、阴性似然比和诊断比值比。诊断性能的评估指标为汇总受试者工作特征曲线及汇总受试者工作特征曲线下面积。
本荟萃分析纳入了8篇符合条件的出版物,共255例晚期NSCLC患者。以肿瘤组织为参照,发现循环肿瘤细胞检测表皮生长因子受体突变状态的合并敏感度、特异度、阳性似然比、阴性似然比和诊断比值比分别为0.82(95%置信区间[CI]:0.50 - 0.95)、0.95(95%CI:0.24 - 1.00)、16.81(95%CI:0.33 - 848.62))、0.19(95%CI:0.06 - 0.64)和86.81(95%CI:1.22 - 6154.15)。汇总受试者工作特征曲线下面积为0.92(95%CI:0.89 - 0.94)。亚组分析显示,血样量、组织学类型、表皮生长因子受体酪氨酸激酶抑制剂治疗以及表皮生长因子受体的循环肿瘤细胞和组织检测方法等因素导致合并特异度存在显著差异。亚组合并敏感度之间未发现显著差异。
我们的荟萃分析证实,在晚期NSCLC患者无法获取肿瘤组织时,循环肿瘤细胞是检测表皮生长因子受体突变的良好替代指标,但需要更精确的技术来提高其临床效率。